SF3B1 and myelodysplastic syndrome: More recently, SF3B1 mutation was incorporated as a defining genetic feature, named MDS with low blasts and SF3B1 mutation by the 2022 WHO classification, and MDS with mutated SF3B1 by the ICC of the same year (2, 3).